NCT03787004

A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects

A Placebo-Controlled, Two-Part Study With Single Dose and Multiple Ascending Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Centrexion Therapeutics · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

A Phase 1, placebo-controlled, two part study with either single dose or multiple increasing oral dose to evaluate the safety, pharmacokinetics, and pharmacodynamics of CNTX-6970 in healthy subjects.

Conditions

• Chronic Pain
• Nociceptive Pain

Interventions

Type	Name	Description
DRUG	CNTX-6970	Oral dose CNTX-6970
OTHER	Placebo	Oral dose placebo

Timeline

• Start date: 2017-08-14
• Primary completion: 2018-08-19
• Completion: 2018-09-26
• First posted: 2018-12-26
• Last updated: 2018-12-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study